Codex DNA Inc
NASDAQ:DNAY
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
US |
C
|
Codex DNA Inc
NASDAQ:DNAY
|
59.8m USD | -1.5 | |
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
225.3B USD | 25.4 | ||
US |
Danaher Corp
NYSE:DHR
|
197.4B USD | 28.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45B USD | 23 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.6B USD | 19.2 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.4T KRW | 33.7 | ||
CH |
Lonza Group AG
SIX:LONN
|
36.6B CHF | 26.6 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 32.2 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.3B USD | 20 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
24.6B USD | 32.5 | ||
US |
Waters Corp
NYSE:WAT
|
20.9B USD | 31.2 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.